Treatment of Ectopic Calcification in Fahr's Disease or Syndrome
NCT05662111
Recruiting
Fahr's disease or syndrome are neurodegenerative diseases in which patients present with bilateral vessel associated calcifications in the basal ganglia. The clinical penetration of Fahr's disease or syndrome is incomplete and heterogeneous comprising of neuropsychiatric signs, cognitive decline, movement disorders, and various other signs (migraine, speech disorders, pain, seizures). The symptoms start between 30 and 50 years and are (slowly) progressive. Symptomatic patients have an increased... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University Medical Center Utrecht, Utrecht, Not set +1 locations
Conditions: Fahr Disease, Fahr Syndrome, Primary Familial Brain Calcification
Register for Updates
Ovarian Cancer Radiomics Approach in CT Led Evaluation
NCT06817174
Recruiting
When patients have suspected or confirmed ovarian cancer standard treatment will involve surgery and chemotherapy. However, as with any treatment, it is challenging to predict treatment response in advance. Before treatment, all patients have a CT scan to describe where the cancer is in order to guide the treatment. There is now a new way to analyse routine scans using advanced computing methods, which may give more information about the ovarian cancer. This is called radiomics which analyses f... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Imperial College NHS Healthcare Trust, London, Not set
Conditions: Ovarian Cancer
Register for Updates
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734
Recruiting
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thromb... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center, Birmingham, Alabama +206 locations
Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Register for Updates
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: XCancer/Dothan Hematology & Oncology - 1114, Dothan, Alabama +159 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931
Recruiting
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +57 locations
Conditions: Advanced Non-Small Cell Lung Cancer
Register for Updates
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786
Recruiting
The purpose of the study is to understand how the study medicine PF-06823859 works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM. This study is seeking participants who: * Are 18 years of age or older or minimum legal adult age as defined per local regulation, whichever is greater * Have active DM or active PM. * Are receiving a stable dose... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona +126 locations
Conditions: Myositis
Register for Updates
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
NCT05652868
Recruiting
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of California San Diego, La Jolla, California +54 locations
Conditions: NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Register for Updates
CMR Versus CT in Coronary Artery Disease
NCT04761991
Recruiting
CONCORD is a prospective observational study evaluating the diagnostic accuracy of cardiovascular magnetic resonance (CMR) and computed tomography with fractional flow reserve (CT-FFR) in patients with suspected coronary artery disease, using invasive fractional flow reserve (FFR) as the reference standard.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Glenfield Hospital, Leicester, Leics
Conditions: Coronary Artery Disease
Register for Updates
Rapid Absorbance-based Detection of Inner Cheek Cell Abnormalities Using Light Spectroscopy for Risk Evaluation of Lung Cancer to Enable Critical Decision Support in Targeted Patient Populations
NCT07051044
Recruiting
Overview Sierra Medical is at the forefront of early detection of lung cancer by creating AIR-DS, a non-invasive early detection test. This innovative approach aims to significantly enhance the early identification of lung cancer, potentially catching it at its most treatable stages through a simple cheek swab. How it works The effectiveness of AIR-DS stems from its ability to identify small biochemical changes in cells from the inner cheek. These biochemical changes can serve as early indicato... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Northumbria Healthcare NHS Foundation Trust, North Shields, Not set +1 locations
Conditions: Lung Cancer
Register for Updates
Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
NCT06560905
Recruiting
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: The Royal Marsden NHS Foundation Trust, London, Not set
Conditions: Malignant Melanoma
Register for Updates
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Southern Cancer Center Pc, Daphne, Alabama +246 locations
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
NCT06972927
Recruiting
The investigators present a diet intervention study, to be conducted as a within-subject design, to assess the effect of the provision of iron biofortified microgreens on iron intake and status in women of reproductive age and postmenopausal women. This will be investigated by providing smoothie kits for 28 days containing these microgreens and determining the impact on iron biomarkers. The investigators will also assess habitual diet, BMI, physical activity and gastrointestinal symptoms. This s... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Rowett Institute, University of Aberdeen, Aberdeen, Not set
Conditions: Iron Biomarkers/Status
Register for Updates